<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30113631</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>20</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1569-8041</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>29</Volume>                    <Issue>8</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>01</Day>                    </PubDate>                </JournalIssue>                <Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title>                <ISOAbbreviation>Ann. Oncol.</ISOAbbreviation>            </Journal>            <ArticleTitle>ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.</ArticleTitle>            <Pagination>                <MedlinePgn>1658-1686</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdy217</ELocationID>            <Abstract>                <AbstractText>The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular cancer (34 panel members attended the conference; an additional two panel members [CB and K-PD] participated in all preparatory work and subsequent manuscript development). The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient. The main topics identified for discussion related to: (1) diagnostic work-up and patient assessment; (2) stage I disease; (3) stage II-III disease; (4) post-chemotherapy surgery, salvage chemotherapy, salvage and desperation surgery and special topics; and (5) survivorship and follow-up schemes. The experts addressed questions relating to one of the five topics within five working groups. Relevant scientific literature was reviewed in advance. Recommendations were developed by the working groups and then presented to the entire panel. A consensus vote was obtained following whole-panel discussions, and the consensus recommendations were then further developed in post-meeting discussions in written form. This manuscript presents the results of the expert panel discussions, including the consensus recommendations and a summary of evidence supporting each recommendation. All participants approved the final manuscript.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Honecker</LastName>                    <ForeName>F</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Tumor and Breast Center ZeTuP, St. Gallen, Switzerland.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Medical Center, Hamburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Aparicio</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Hospital Universitari i Politècnic la Fe, Valencia, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Berney</LastName>                    <ForeName>D</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Beyer</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bokemeyer</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Medical Center, Hamburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cathomas</LastName>                    <ForeName>R</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Hematology, Kantonsspital Graubünden, Chur, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Clarke</LastName>                    <ForeName>N</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cohn-Cedermark</LastName>                    <ForeName>G</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology-Pathology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Daugaard</LastName>                    <ForeName>G</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dieckmann</LastName>                    <ForeName>K-P</ForeName>                    <Initials>KP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Urology, Asklepios Klinik Altona, Hamburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fizazi</LastName>                    <ForeName>K</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fosså</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Oslo University Hospital Radiumhospitalet, Oslo, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Germa-Lluch</LastName>                    <ForeName>J R</ForeName>                    <Initials>JR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Catalan Institute of Oncology (ICO), Barcelona University, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Giannatempo</LastName>                    <ForeName>P</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto dei Tumori, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gietema</LastName>                    <ForeName>J A</ForeName>                    <Initials>JA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gillessen</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>University of Bern, Bern, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haugnes</LastName>                    <ForeName>H S</ForeName>                    <Initials>HS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, University Hospital of North Norway, Tromsø, Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institute of Clinical Medicine, UIT - The Arctic University, Tromsø, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Heidenreich</LastName>                    <ForeName>A</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Urology, Uro-Oncology, Robot-assisted and Specialised Urologic Surgery, University of Cologne, Cologne, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hemminki</LastName>                    <ForeName>K</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Huddart</LastName>                    <ForeName>R</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiotherapy and Imaging, The Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jewett</LastName>                    <ForeName>M A S</ForeName>                    <Initials>MAS</Initials>                    <AffiliationInfo>                        <Affiliation>Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Joly</LastName>                    <ForeName>F</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Urology-Gynaecology, Centre Francois Baclesse, Caen, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lauritsen</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lorch</LastName>                    <ForeName>A</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Urology, Genitourinary Medical Oncology, Heinrich-Heine University Hospital Düsseldorf, Düsseldorf, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Necchi</LastName>                    <ForeName>A</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto dei Tumori, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nicolai</LastName>                    <ForeName>N</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Urology and Testis Surgery Unit, Fondazione IRCCS Istituto dei Tumori, Milan, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Oing</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Medical Center, Hamburg, Germany.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Oldenburg</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Akershus University Hospital, Lørenskog, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ondruš</LastName>                    <ForeName>D</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>1st Department of Oncology, St. Elisabeth Cancer Institute, Comenius University Faculty of Medicine, Bratislava, Slovak Republic.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Papachristofilou</LastName>                    <ForeName>A</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Powles</LastName>                    <ForeName>T</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sohaib</LastName>                    <ForeName>A</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Royal Marsden Hospital, Sutton, UK.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ståhl</LastName>                    <ForeName>O</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Skane University Hospital, Lund University, Lund, Sweden.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tandstad</LastName>                    <ForeName>T</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>The Cancer Clinic, St. Olavs Hospital, Trondheim, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Toner</LastName>                    <ForeName>G</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Horwich</LastName>                    <ForeName>A</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>The Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Ann Oncol</MedlineTA>            <NlmUniqueID>9007735</NlmUniqueID>            <ISSNLinking>0923-7534</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>17</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30113631</ArticleId>            <ArticleId IdType="pii">5063556</ArticleId>            <ArticleId IdType="doi">10.1093/annonc/mdy217</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>